



Endologix
Investor Relations Department
2 Musick
Irvine, CA 92618
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ELGX

Last Trade:	4.06
Trade Time:	4:00 PM ET Feb 23, 2018
Change:	0.01 ▲ (+0.247%)
Day Range	4.01 - 4.10
52-Week Range	3.75 - 7.66
Volume	354,253

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

Stock Performance



Press Releases [\[View all \]](#)

Feb 21, 2018

[John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.](#)

Feb 21, 2018

[Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)

Feb 5, 2018

[Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study](#)

Jan 30, 2018

[Endologix, Inc. to Present at the Leerink Partners 7th Annual Global Healthcare Conference](#)

Jan 29, 2018

[Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)